TIDMNSCI

RNS Number : 1367U

NetScientific PLC

05 April 2016

("NetScientific" or the "Company" or the "Group")

Netscientific Appoints Ian Postlethwaite as Chief Financial Officer

London, UK - 5(th) April 2016 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic biomedical and healthcare technology group, is pleased to announce that Ian Postlethwaite has accepted the role as Chief Financial Officer. Ian will join the Company and the Board as soon as his current employer has appointed a suitable successor and allowed time for an orderly handover. A subsequent announcement detailing Ian's start date will be made in due course.

Ian Postlethwaite is currently the Finance Director and Company Secretary of Allergy Therapeutics plc, where he has held the roles since May 2002. Ian previously held senior finance and executive management positions with AFS (1997-2002), Ericsson (1994-1997) and Phillips Electronics (1989-1994). Ian is a Fellow of the Chartered Association of Certified Accountants. He graduated from Aston University in 1985 with a BSc (Hons) in Geological Sciences.

Commenting on the appointment, Sir Richard Sykes, Chairman of NetScientific, said: "I am delighted to welcome Ian to NetScientific as our new Chief Financial Officer. His wealth of experience at Board level in raising capital for listed growth companies with international operations in the healthcare sector will be a huge asset to the Company as we move forward with our new focus on digital health, diagnostics and therapeutics.

"We very much look forward to working with Ian as he becomes a pivotal member of our team. Until he commences Mark Nanovich will continue in his role as Interim CFO, and we would like to thank Mark for his continued contribution in helping to support the business during our recent period of transition."

Ian Postlethwaite commented: "I am excited to be joining NetScientific - this is a rapidly progressing group with an exciting portfolio of high-quality assets focused on dynamic new areas in healthcare. I look forward to working with the team to build value."

Ian David Postlethwaite, aged 53 years, has been a director of the following companies during the five years preceding the date of this announcement:

 
 Current directorships                              Past Directorships 
Allergy Therapeutics plc                            Allergy Therapeutics Developments 
Allergy Therapeutics (Holdings) Limited             Limited 
Bencard Allergie GmbH 
Allergy Therapeutics Italia s.r.l. 
Allergy Therapeutics Iberia S.L. 
Sussex Port Forwarding Limited 
Shoreham Port Developments And Investments Limited 
Teomed AG

There is no further information to be disclosed under Schedule Two paragraph (g) of the AIM Rules for Companies.

- Ends -

For more information, please contact:

 
 NetScientific                            Tel: +44 (0)20 3514 1800 
  François R. Martelet, 
  M.D., CEO 
  Mark Nanovich, Interim 
  CFO 
 Investec (NOMAD and                      Tel: +44 (0)20 7597 4000 
  broker) 
  Gary Clarence / Daniel 
  Adams 
  Consilium Strategic                     Tel: +44 (0)20 3709 5700 
   Communications                netscientific@consilium-comms.com 
   Mary-Jane Elliott / 
   Chris Gardner / Jessica 
   Hodgson / Chris Welsh 
   / Laura Thornton

About NetScientific Plc

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.netscientific.net.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOALFFEISRISIIR

(END) Dow Jones Newswires

April 05, 2016 02:00 ET (06:00 GMT)

Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024 Click aqui para mais gráficos Netscientific.
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024 Click aqui para mais gráficos Netscientific.